Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo FY 1995 sales increase 7% to $717.1 mil., following 10% gain in fourth quarter.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO FY 1995 SALES INCREASE 7.1% TO $717.1 MIL. for the year ended June 30. Sales in the fourth quarter rose 10% to $174.4 mil. As expected, the company's analgesic sales continued to be soft into the final quarter, Perrigo noted. The company has cited increased competition in the analgesics market due, in part, to Procter & Gamble's launch of Aleve as well as a mild cold and flu season as negatively affecting its sales

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel